Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
57 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
Rank Status Study
21 Unknown  Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: ifosfamide;   Procedure: hyperthermia treatment
22 Recruiting INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: IDO1 Inhibitor INCB024360;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
23 Recruiting Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
Condition: Spontaneous Bacterial Peritonitis (SBP).
Interventions: Drug: cefepime + Albumin;   Drug: Imipenem + Albumin
24 Recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
25 Recruiting Different Retraining Methods vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis
Condition: Peritonitis
Intervention: Behavioral: operation inspection
26 Unknown  Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial
Conditions: Spontaneous Bacterial Peritonitis;   Liver Cirrhosis
Interventions: Drug: Probiotics and Placebo;   Drug: Probiotics and Norfloxacin
27 Recruiting The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements
Condition: Pneumoperitoneum
Intervention: Procedure: Pneumoperitoneum and SVV/PPV
28 Unknown  Diagnostic of Spontaneous Bacterial Peritonitis
Condition: Spontaneous Bacterial Peritonitis
Intervention: Other: Ascite liquid puncture
29 Not yet recruiting Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery
Conditions: Malignant Gastrointestinal Neoplasm;   Malignant Peritoneal Neoplasm
Interventions: Device: Management of Therapy Complications Fitbit Zip (portable pedometer device);   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
30 Recruiting Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum
Conditions: Hepatic Dysfunction Transient;   Renal Function Disorder
Interventions: Other: TEAS pretreatment;   Other: TEAS treatment
31 Recruiting Functional Genomic Influences on Disease Progression and Outcome in Sepsis
Conditions: Pneumonia;   Peritonitis
Intervention:
32 Recruiting Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Conditions: Spontaneous Bacterial Peritonitis;   Ascites;   Liver Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Norfloxacin
33 Recruiting A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Condition: Recurrent Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Cancer,
Interventions: Biological: Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells;   Biological: SB--‐485232 (Human recombinant Interleukin--‐18)
34 Recruiting A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Oral rucaparib
35 Recruiting Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Primary Peritoneal Cancer
Intervention: Drug: Tivozanib
36 Unknown  Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
Condition: Peritonitis
Interventions: Drug: ceftazidime+ciprofloxacin;   Drug: ceftazidime monotherapy;   Drug: cefazolin+gentamicin;   Drug: cefazolin monotherapy
37 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: folate receptor alpha-loaded dendritic cell vaccine;   Other: laboratory biomarker analysis
38 Recruiting Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
Condition: Spontaneous Bacterial Peritonitis
Interventions: Drug: Rifaximin;   Drug: Ciprofloxacin
39 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:
40 Not yet recruiting Adjuvant HIPEC in High Risk Colon Cancer
Conditions: Colorectal Neoplasms;   Peritoneal Neoplasms
Interventions: Procedure: Adjuvant HIPEC (open/laparoscopic);   Drug: Standard adjuvant systemic chemotherapy;   Procedure: Diagnostic laparoscopy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-57) Show next page of results    Last Page
Indicates status has not been verified in more than two years